Summary
Boston Scientific Corporation (BSX) filed an 8-K on November 18, 2004, to report on the successful completion of a public offering of debt securities. The company issued $500 million in aggregate principal amount of notes, consisting of $250 million of 4.250% Notes due 2011 and $250 million of 5.125% Notes due 2017. The offering was conducted under the company's existing shelf registration statement and was managed by underwriters including Merrill Lynch, UBS Securities, and Wachovia Capital Markets. The net proceeds from this offering are earmarked for repaying outstanding commercial paper borrowings and for general corporate purposes. This debt issuance signals a strategic move by Boston Scientific to manage its short-term liabilities and strengthen its overall financial structure. Investors should note the specific interest rates and maturity dates of the new notes, which indicate the cost of capital for these borrowings and the company's future debt obligations.
Key Highlights
- 1Completed a public offering of $500 million in aggregate principal amount of notes.
- 2Issued $250 million of 4.250% Notes due 2011.
- 3Issued $250 million of 5.125% Notes due 2017.
- 4The offering was conducted under the company's existing shelf registration statement.
- 5Proceeds will be used to repay commercial paper borrowings.
- 6Proceeds will also be used for general corporate purposes.
- 7Key underwriters included Merrill Lynch, UBS Securities, and Wachovia Capital Markets.